Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT - Wikidata - wikimedia - TriplyDB

Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT

Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT

http://www.wikidata.org/entity/Q34995973

about

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report A Review of Imaging Methods for Prostate Cancer Detection.Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging GCPII imaging and cancer.PET Tracer 18F-Fluciclovine Can Detect Histologically Proven Bone Metastatic Lesions: A Preclinical Study in Rat Osteolytic and Osteoblastic Bone Metastasis Models.Positron emission tomography (PET) in primary prostate cancer staging and risk assessment Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.[(18)F](2S,4S)-4-(3-Fluoropropyl)glutamine as a tumor imaging agent.Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.AEG-1 promoter-mediated imaging of prostate cancer.Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis Synthesis, Radiolabeling, and Biological Evaluation of (R)- and (S)-2-Amino-5-[(18)F]fluoro-2-methylpentanoic Acid ((R)-, (S)-[(18)F]FAMPe) as Potential Positron Emission Tomography Tracers for Brain Tumors.Molecular imaging of prostate cancer: PET radiotracers.Synthesis and evaluation of 18F labeled alanine derivatives as potential tumor imaging agents PET/CT in prostate cancer: non-choline radiopharmaceuticals.Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake Reproducibility and reliability of anti-3-[¹⁸F]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.Application of metabolic PET imaging in radiation oncology.PET imaging in prostate cancer: focus on prostate-specific membrane antigen Functional and molecular imaging of localized and recurrent prostate cancer.Therapeutic modulation of prostate cancer metastasis.Nuclear medicine in urological cancers: what is new?Imaging biomarkers in prostate cancer: role of PET/CT and MRI.The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis.Initial prostate cancer diagnosis and disease staging--the role of choline-PET-CT.NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics.PET imaging of recurrent and metastatic prostate cancer with novel tracers.Imaging of local recurrence in prostate cancer.Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial.Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters.PET Tracers Beyond FDG in Prostate Cancer.MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model Preliminary clinical experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT imaging in prostate cancer patients.Phase IIa Clinical Trial of Trans-1-Amino-3-(18)F-Fluoro-Cyclobutane Carboxylic Acid in Metastatic Prostate Cancer.Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.

P2860

Q26747480-E79B770D-799A-4F8C-B312-E207BB392F16 Q26766398-D22E5481-B274-4225-873F-1886E385F793 Q28074669-5D5257F3-4BE9-4A01-872B-30970A33546D Q33827632-05C4156D-9272-4597-9B5C-71C1EDDB43A9 Q33836426-8FD3BD78-7166-414D-B18B-A05F97B86610 Q33890153-5BA907DA-1305-409E-AFDF-767316832DAF Q34139498-CE60033C-6AC4-4C43-BC01-F6CECDAABD21 Q34228828-7D9B5DDA-6A54-4154-AA43-44892EC98D99 Q34451031-DABFE3EB-9D52-4869-BD35-0864B912DCDD Q34473613-F77E3CCB-0433-43A6-88FE-439AD5560F8E Q34522627-26E5F44F-3AA7-42AC-9412-7DE3BC368138 Q34522714-3E9E3616-77B0-46C5-BE14-9E948D4D73BC Q34681143-E1218D5E-32A7-4932-811A-EA40F7971280 Q35764792-E7CA49FC-77ED-4652-8BB4-2E2A7BF641AC Q36129937-EFCC6CE2-4C5F-4092-9D85-F8EE4C7EA02C Q36205180-69ABA637-31FC-4C41-8043-043C43FFEED0 Q36308766-0C01CE3A-FAEB-41F9-8643-F264002C2722 Q36533826-9CE22323-9E51-4012-B5C4-FE752ED70EC0 Q36839766-0712C3A5-FB6D-41B7-AB86-5D4FEB2EBF6C Q37086178-4F38924D-1E2C-425F-BAEA-971CDD030320 Q37092020-705AA323-37AF-4AE7-B2A9-8AAA339CB43E Q37580845-AD8F2FE0-1222-4129-BD92-7C78D582698E Q38099369-79E17990-0FD8-4F6E-9412-79FEDED99A49 Q38104639-4E019828-A3CE-48F7-A9C1-F1F2CD2F6A71 Q38182140-5DFD94A1-BA50-4E9E-A24A-415713F5D8FD Q38268168-F5255F96-5E0C-4293-8CC4-85A007393B9D Q38321182-A7F504FB-1F47-4F47-8885-09E731A514B0 Q38439189-4C9BB2C2-E2AF-4616-B352-A2BC5A69CC21 Q38564109-5D4881DB-9400-4E59-AF77-00C0F3D5EBD9 Q38767020-E9E7F516-CDE5-4C90-9BCE-9DFA0CF6EB8D Q38831029-594E38D2-DD5B-4CD0-A115-F716B97DC937 Q38852724-908310D7-5783-4ADA-AFEC-2E2A0A21D237 Q38924532-B760CBEB-5A66-45B7-9914-B484F8215204 Q38982759-F1455BE1-B26E-4FB1-82B4-EA3959BBC19F Q38983205-A5E59CDA-6644-48B7-846B-C7DEFFA64EEC Q39003086-91DD3DB2-3035-429C-84AD-8CAC16A07AA0 Q39433320-EDE22A62-ECDF-4A3B-B1B0-EDAEBF82AF55 Q40741628-F39B94DE-74BB-4CA9-A3E3-42DAB79D45AC Q41862609-3737AA73-6DB6-49CD-B777-23F45D895ACE Q42060482-EEB09016-BB83-46C1-BB8A-CDDCC555AE05

P2860

Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT

http://www.wikidata.org/entity/Q34995973

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Detection of recurrent prostat ...... In-capromab pendetide SPECT/CT

@ast

Detection of recurrent prostat ...... In-capromab pendetide SPECT/CT

@en

Detection of recurrent prostat ...... In-capromab pendetide SPECT/CT

@nl

type

label

Detection of recurrent prostat ...... In-capromab pendetide SPECT/CT

@ast

Detection of recurrent prostat ...... In-capromab pendetide SPECT/CT

@en

Detection of recurrent prostat ...... In-capromab pendetide SPECT/CT

@nl

prefLabel

Detection of recurrent prostat ...... In-capromab pendetide SPECT/CT

@ast

Detection of recurrent prostat ...... In-capromab pendetide SPECT/CT

@en

Detection of recurrent prostat ...... In-capromab pendetide SPECT/CT

@nl

P1433

Q34995973-3BFBC046-6755-4112-9169-C31AE62999EE

P1476

Q34995973-49422D87-BFF4-4CD4-9DC6-3D67FE999EB4

P2093

Q34995973-309FA867-F66C-4B7B-844B-AE2688E76AE4

Q34995973-6096D911-0F9B-4AF7-91DA-E893D243F33D

Q34995973-92382432-F5A0-4F79-ABAF-C5368A5A5B42

Q34995973-94CEF5D6-8919-4AEF-9C26-54D9000FBC96

Q34995973-C8ADCDDA-A8AA-4709-866D-BBA0DF3BF153

Q34995973-CABCA7AC-38CD-4478-A34E-EA9F3B629D6B

Q34995973-D0A5B4DE-B006-47FC-8872-B2C8EAA1E141

Q34995973-DE4AFAF6-3F72-48CF-8A7F-86195CE6E792

Q34995973-E0F56DF4-6BC9-498A-86E1-6E75C12C07E8

Q34995973-E134BB82-663A-4398-9428-DD0F5C2B015A

P2860

Q34995973-09F62BF9-0DFD-4012-9FC1-68FA5D4732A1

Q34995973-0FD51752-6D39-4F99-A5D5-2F587A1D65A1

Q34995973-1AE2FE80-8EDB-42FC-A4C1-9999D844F898

Q34995973-1B4EB9F5-BACF-4805-87C5-7FDCA1E17B03

Q34995973-21964D71-7B85-4CAD-9C92-806F8CDFCF55

Q34995973-249988A6-2FAD-43B9-BE45-3817782135AA

Q34995973-25003565-6F05-48F2-AD68-CCA8C27ED799

Q34995973-26408798-9739-4DD2-84BF-403559990280

Q34995973-2724797B-08F2-4D7B-96E6-16FB37EF0302

Q34995973-2FAAC2C4-3BAB-4F59-924C-9659D2132B8F

P304

Q34995973-0861628A-A13E-44B5-B801-198FC8C22570

P31

Q34995973-50688BCE-D8BA-43C4-A2EA-1BC70651919F

P356

Q34995973-BE831FB6-D8C5-4EB3-99E6-5C5732336ECF

P407

Q34995973-AE1D28E5-CFCD-4CD0-8B5F-494B4871FEB9

P433

Q34995973-EDBB7D9A-9487-4FAB-B45F-6239E3B0C901

P478

Q34995973-88503688-8B84-4FC2-A54A-EF3E81569BCF

P50

Q34995973-E53A439F-A141-4E36-A0CF-81D202354F89

P577

Q34995973-A093B4FE-84D6-4041-BBF2-3E45104FA4E8

P5875

Q34995973-B23F7A8C-1854-4049-ADFF-01582BB23BD7

P698

Q34995973-57BE59EE-38C7-4741-90CC-03414115A4E4

P932

Q34995973-F9A66952-2654-4886-B51A-36569F1D2D0D

P356

RADIOL.11102023

P1433

P1476

Detection of recurrent prostat ...... In-capromab pendetide SPECT/CT

@en

P2093

Bital Savir-Baruch

http://www.w3.org/2001/XMLSchema#string

F DuBois Bowman

http://www.w3.org/2001/XMLSchema#string

Jonathon A Nye

http://www.w3.org/2001/XMLSchema#string

Mark M Goodman

http://www.w3.org/2001/XMLSchema#string

Melinda M Lewis

http://www.w3.org/2001/XMLSchema#string

Peter J Rossi

http://www.w3.org/2001/XMLSchema#string

Peter T Nieh

http://www.w3.org/2001/XMLSchema#string

Raghuveer K Halkar

http://www.w3.org/2001/XMLSchema#string

Viraj A Master

http://www.w3.org/2001/XMLSchema#string

Weiping Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Positron emission tomography imaging of prostate cancer

Cancer statistics, 2010

Indium-111 capromab pendetide in the management of recurrent prostate cancer

Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer.

Natural history of progression after PSA elevation following radical prostatectomy.

In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT.

Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges.

Challenges in clinical prostate cancer: role of imaging.

Noninvasive detection of clinically occult lymph-node metastases in prostate cancer.

NCCN clinical practice guidelines in oncology: prostate cancer.

P304

852-861

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1148/RADIOL.11102023

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

259

http://www.w3.org/2001/XMLSchema#string

P50

David M Schuster

P577

2011-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51051934

http://www.w3.org/2001/XMLSchema#string

P698

21493787

http://www.w3.org/2001/XMLSchema#string

P932

3099047

http://www.w3.org/2001/XMLSchema#string